Table 1.
Characteristics of 115 Cancer Patients With Invasive Aspergillosis (IA)
| Characteristic | Patients |
| Sex, male:female | 68:47 |
| Age, median years (range) | 60 (26–81) |
| Multiple myeloma as underlying disease, no. (%)a | 104 (90) |
| Antineoplastic treatment | |
| Chemotherapyb | 60 (52) |
| HCTc | 55 (48) |
| Prior HCT, median no. (range) | 1 (0–4) |
| Receipt of corticosteroids during the 60 days preceding IA diagnosis, no. (%) | 105 (91) |
| Neutropenia at diagnosis of IA, no. (%)d | 100 (87) |
| Antifungal therapy, no. (%) | |
| Voriconazole | 66 (57) |
| Liposomal amphotericin B | 28 (24) |
| Othere | 14 (13) |
| None | 7 (6) |
| Time from diagnosis of IA to antifungal therapy, median days (range) | 3 (0–28) |
| Duration of antifungal therapy, median days (range) | 23 (1–82) |
Abbreviation: HCT, hematopoietic stem cell transplantation.
a
Other underlying diseases: acute myeloid leukemia (4 patients), non-Hodgkin lymphoma (3 patients), solid tumor (2 patients), chronic lymphocytic leukemia (1 patient), and myelofibrosis (1 patient).
b
There were 50 myelosuppressive and 10 nonmyelosuppressive regimens; 50 autologous and 5 allogeneic HCT.
c
Seven patients did not receive treatment because of early death (2) or spontaneous response after bone marrow recovery (5).
d
Neutropenia was defined as absolute neutrophil count <500/mm3.
e
Other treatments included combinations of various agents: voriconazole, liposomal amphotericin B, micafungin, or anidulafungin.